FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384153555> ?p ?o ?g. }

• W4384153555 abstract "ABSTRACT Background Few studies have evaluated the treatment of immunoglobulin A nephropathy (IgAN) patients with nephrotic syndrome (NS) and mesangioproliferative glomerulonephritis (MPGN). The aim of this study was to compare the therapeutic effects of oral glucocorticoids (GCS) combined with intravenous cyclophosphamide (CTX) and oral GCS alone in the treatment of the MPGN-IgAN patients with NS. Methods Biopsy-proven primary IgAN patients who were aged ≥14 years at diagnosis, had coexistent NS and MPGN and estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m2, and were treated by oral GCS combined with intravenous CTX or oral GCS alone for 6–12 months were retrospectively included. The patients in the GCS + CTX (prednisone 0.6–0.8 mg/kg/day and intravenous CTX 0.6–1.0 g monthly) or GCS (prednisone 0.8–1 mg/kg/day) group were rather matched at a 1:1 ratio on key characteristics by propensity score matching. The primary outcome was defined as either complete remission or partial remission at Month 24. The secondary outcome was a composite renal endpoint defined as a 50% decline in eGFR, doubling of serum creatinine or progression to end-stage kidney disease. Results Among the 146 IgAN patients who met the inclusion criteria, 42 patients were enrolled in the GCS + CTX group, and 42 patients were enrolled in the GCS group after propensity score matching. The clinical and histological parameters were similar between the two groups. Remission occurred more frequently in the GCS + CTX group at Month 6 (88.1% vs 52.4%, P &lt; 0.001), Month 12 (88.1% vs 56.1%, P = 0.001) and Month 24 (85.0% vs 47.5%, P &lt; 0.001) than in the GCS group. Moreover, subgroup analysis revealed that the higher response rate at Month 24 in the GCS + CTX group than in the GCS group was also present in different subgroups defined by sex, age, eGFR or Oxford MEST-C. Notably, we found that eGFR decreased at a lower rate in patients from the GCS + CTX group than in patients from the GCS group [eGFR slope: 0.05(–3.09, 3.67) vs –2.56 (–11.30, 0.86) mL/min/1.73 m2/year, P = 0.03]. Based on multivariate Cox regression analysis, GCS + CTX treatment was found to be independently associated with a decrease in risk for the composite endpoint after adjusted by the International Risk Prediction Score with race (hazard ratio = 0.17, 95% confidence interval 0.04–0.83, P = .03). There was no significant difference in adverse events (50.0% vs 42.9%, P = 0.51) or serious adverse events (7.1% vs 11.9%, P = .71) between the two groups. Conclusions Oral GCS combined with intravenous CTX is superior to GCS alone in treating MPGN-IgAN patients combined with NS. As the retrospective design and small sample size, our findings need to be validated by a prospective study." @default.
• W4384153555 created "2023-07-14" @default.
• W4384153555 creator A5013879989 @default.
• W4384153555 creator A5015961049 @default.
• W4384153555 creator A5016396916 @default.
• W4384153555 creator A5020875892 @default.
• W4384153555 creator A5024994504 @default.
• W4384153555 creator A5025721227 @default.
• W4384153555 creator A5026262593 @default.
• W4384153555 creator A5034464441 @default.
• W4384153555 creator A5042301918 @default.
• W4384153555 creator A5044520474 @default.
• W4384153555 creator A5047297167 @default.
• W4384153555 creator A5049194163 @default.
• W4384153555 creator A5072389210 @default.
• W4384153555 creator A5090977257 @default.
• W4384153555 creator A5092459685 @default.
• W4384153555 date "2023-07-13" @default.
• W4384153555 modified "2023-10-16" @default.
• W4384153555 title "Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis" @default.
• W4384153555 cites W1971947423 @default.
• W4384153555 cites W1985151920 @default.
• W4384153555 cites W2018055120 @default.
• W4384153555 cites W2021230907 @default.
• W4384153555 cites W2022975241 @default.
• W4384153555 cites W2041677815 @default.
• W4384153555 cites W2074850565 @default.
• W4384153555 cites W2110610804 @default.
• W4384153555 cites W2125785855 @default.
• W4384153555 cites W2134949867 @default.
• W4384153555 cites W2136464172 @default.
• W4384153555 cites W2155965977 @default.
• W4384153555 cites W2157894387 @default.
• W4384153555 cites W2160421164 @default.
• W4384153555 cites W2161458854 @default.
• W4384153555 cites W2165786389 @default.
• W4384153555 cites W2168416668 @default.
• W4384153555 cites W2186629139 @default.
• W4384153555 cites W2206113961 @default.
• W4384153555 cites W2223268479 @default.
• W4384153555 cites W2517246046 @default.
• W4384153555 cites W2600347335 @default.
• W4384153555 cites W2602196428 @default.
• W4384153555 cites W2741457765 @default.
• W4384153555 cites W2937346600 @default.
• W4384153555 cites W2973946552 @default.
• W4384153555 cites W3080629152 @default.
• W4384153555 cites W3200479416 @default.
• W4384153555 cites W4239867451 @default.
• W4384153555 cites W4280506915 @default.
• W4384153555 cites W4306757577 @default.
• W4384153555 cites W7996314 @default.
• W4384153555 doi "https://doi.org/10.1093/ckj/sfad164" @default.
• W4384153555 hasPublicationYear "2023" @default.
• W4384153555 type Work @default.
• W4384153555 citedByCount "0" @default.
• W4384153555 crossrefType "journal-article" @default.
• W4384153555 hasAuthorship W4384153555A5013879989 @default.
• W4384153555 hasAuthorship W4384153555A5015961049 @default.
• W4384153555 hasAuthorship W4384153555A5016396916 @default.
• W4384153555 hasAuthorship W4384153555A5020875892 @default.
• W4384153555 hasAuthorship W4384153555A5024994504 @default.
• W4384153555 hasAuthorship W4384153555A5025721227 @default.
• W4384153555 hasAuthorship W4384153555A5026262593 @default.
• W4384153555 hasAuthorship W4384153555A5034464441 @default.
• W4384153555 hasAuthorship W4384153555A5042301918 @default.
• W4384153555 hasAuthorship W4384153555A5044520474 @default.
• W4384153555 hasAuthorship W4384153555A5047297167 @default.
• W4384153555 hasAuthorship W4384153555A5049194163 @default.
• W4384153555 hasAuthorship W4384153555A5072389210 @default.
• W4384153555 hasAuthorship W4384153555A5090977257 @default.
• W4384153555 hasAuthorship W4384153555A5092459685 @default.
• W4384153555 hasBestOaLocation W43841535551 @default.
• W4384153555 hasConcept C126322002 @default.
• W4384153555 hasConcept C126894567 @default.
• W4384153555 hasConcept C134018914 @default.
• W4384153555 hasConcept C159641895 @default.
• W4384153555 hasConcept C203092338 @default.
• W4384153555 hasConcept C2776694085 @default.
• W4384153555 hasConcept C2776755627 @default.
• W4384153555 hasConcept C2778720950 @default.
• W4384153555 hasConcept C2778930706 @default.
• W4384153555 hasConcept C2779561371 @default.
• W4384153555 hasConcept C2780091579 @default.
• W4384153555 hasConcept C2780306776 @default.
• W4384153555 hasConcept C2780368995 @default.
• W4384153555 hasConcept C2781184683 @default.
• W4384153555 hasConcept C535046627 @default.
• W4384153555 hasConcept C555293320 @default.
• W4384153555 hasConcept C71924100 @default.
• W4384153555 hasConcept C90924648 @default.
• W4384153555 hasConceptScore W4384153555C126322002 @default.
• W4384153555 hasConceptScore W4384153555C126894567 @default.
• W4384153555 hasConceptScore W4384153555C134018914 @default.
• W4384153555 hasConceptScore W4384153555C159641895 @default.
• W4384153555 hasConceptScore W4384153555C203092338 @default.
• W4384153555 hasConceptScore W4384153555C2776694085 @default.
• W4384153555 hasConceptScore W4384153555C2776755627 @default.
• W4384153555 hasConceptScore W4384153555C2778720950 @default.
• W4384153555 hasConceptScore W4384153555C2778930706 @default.

• next